Standard Family Office’s Neurocrine Biosciences NBIX Stock Holding History

Standard Family Office’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-377	Closed	-$40K	–	296
2022 Q3	$40K	Hold	377	–	–	0.02%	151
2022 Q2	$37K	Buy	+377	New	+$34.8K	0.37%	65
2022 Q1	–	Sell	-525	Closed	-$45K	–	179
2021 Q4	$45K	Buy	+525	New	+$48.3K	0.4%	57
2021 Q3	–	Sell	-663	Closed	-$65K	–	366
2021 Q2	$65K	Hold	663	–	–	0.01%	225
2021 Q1	$64K	Hold	663	–	–	0.02%	239
2020 Q4	$64K	Buy	+663	New	+$64K	0.02%	242

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Standard Family Office's NBIX Position: Q4 2022 in Review

Standard Family Office sold out of Neurocrine Biosciences (NBIX) in Q4 2022, closing a stake of 377 shares — an estimated $40K sold.

Standard Family Office first reported a position in NBIX in Q4 2020 and held it in 6 quarters. The position peaked at $65K in Q2 2021. 529 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

Standard Family Office reported no remaining Neurocrine Biosciences position as of Q4 2022 after selling out during the quarter.
Standard Family Office sold 377 Neurocrine Biosciences shares in Q4 2022, an estimated $40K.
Standard Family Office first reported a position in Neurocrine Biosciences in Q4 2020 and held it in 6 quarters.
Standard Family Office's Neurocrine Biosciences position peaked at $65K in Q2 2021.
529 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on Standard Family Office's 13F filing for Q4 2022, filed 13 Feb 2023.